Table 2 Trial participant characteristics and intravenous treatment received.
| Variable | Antioxidant | Placebo | p Value |
|---|---|---|---|
| Number of subjects | 22 | 21 | |
| Age (SD)* | 64 (13) | 71 (14) | 0.081 |
| Sex (% male)† | 36% | 33% | 1.00 |
| APACHE score | |||
| At admission (SD)* | 10.5 (3.4) | 11.0 (3.5) | 0.67 |
| At randomisation (SD)* | 11.0 (2.7) | 11.2 (3.2) | 0.80 |
| MODS at admission (IQR)‡ | 1.36 (0–2) | 1.19 (0–2) | 0.90 |
| LODS at admission (IQR)‡ | 3.05 (1–4.5) | 1.90 (1–3) | 0.35 |
| Aetiology§ | 0.58 | ||
| Gallstone | 12 | 14 | |
| Alcohol | 5 | 2 | |
| Unknown | 1 | 2 | |
| Idiopathic | 1 | 1 | |
| Immunosuppression | 1 | 1 | |
| Hyperlipidaemia | 2 | 0 | |
| Post ERCP | 0 | 1 | |
| Days of intravenous treatment | 4.1 (3.0) | 4.7 (2.0) | 0.42 |
MODS, Marshall organ dysfunction score; LODS, logistic organ dysfunction score; ERCP, endoscopic retrograde cholangiopancreatography; IQR, interquartile range.
*Unpaired two sample Student t test.
†Fisher's exact test (two sided).
‡Mann‐Whitney U test.
§χ2 test (2 × k) without trend.